Ciclosporin (Ikervis®) for the treatment of severe keratitis in adult patients with the dry eye syndrome

Zorginstituut Nederland has completed its assessment whether ciclosporin (Ikervis®) for the treatment of severe keratitis in adult patients with the dry eye syndrome, can be accepted into the Medicine Reimbursement System (GVS).

Registered indication

Ciclosporin 0.1% (Ikervis®) is registered for the treatment of severe keratitis in adult patients with dry eye syndrome which has not improved despite treatment with tear substitutes. Ikervis® is available as a cationic emulsion containing 0.1% ciclosporin. Each ml contains 1 mg ciclosporin. The recommended dose is one drop of Ikervis® once daily to be applied to the affected eye(s) at bedtime.

Zorginstituut's advice

The Zorginstituut advices the Minister of Health, Welfare and Sport (VWS) to accept ciclosporin (Ikervis®) into the Medicine Reimbursement System (GVS). Based on the criteria for interchangeability, ciclosporin 0.1% (Ikervis®) is not eligible for inclusion on List 1A. Based on the mentioned considerations in the assessment, the Zorginstituut advises the Minister to include ciclosporin 0.1% (Ikervis®) on List 1B of the Health Insurance Decree. There is no reimbursement limit for medicinal products on this list.

This report is a summary of recommendations by Zorginstituut Nederland. The original text of this excerpt is in Dutch.